Use of tumour markers in monitoring the course of ovarian cancer
There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials. The situations where measurement of CA 125 could alter the management of individual patients during therapy and at re...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 1999, Vol.10, p.21-27 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 27 |
|---|---|
| container_issue | |
| container_start_page | 21 |
| container_title | Annals of oncology |
| container_volume | 10 |
| creator | RUSTIN, G. J. S NELSTROP, A. E BENTZEN, S. M PICCART, M. J BERTELSEN, K |
| description | There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials.
The situations where measurement of CA 125 could alter the management of individual patients during therapy and at relapse were critically analysed. Precise definitions for response according to CA 125 were first developed and tested on 989 patients receiving first line therapy and have since been tested on over 2000 patients in phase 2 trials. Precise definitions for progression were developed from 71 patients during and on 255 patients both during and after initial chemotherapy.
In individual patient management, progression on initial chemotherapy can be demonstrated by serial rise in CA 125 suggesting the need for a change in therapy. A confirmed doubling of CA 125 from the upper limit of normal during follow up accurately predicts relapse. This endpoint needs prospective testing for use in clinical trials. Precise definitions of response based on a 50% or 75% fall in CA 125 levels accurately predicts whether a cytotoxic agent is active against ovarian cancer.
Precise definitions of response based on CA 125 should be used in phase 2 trials of new cytotoxic drugs. |
| doi_str_mv | 10.1016/s0923-7534(20)31480-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69717010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69717010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2960-3f2b7bd0a361f232cc7167fd81e8b0d328e1be19e908dee52bafc976854ab9723</originalsourceid><addsrcrecordid>eNpNkE1LxDAQhoMo7rr6E5QcRPRQnSRt0tyUxS9Y8KB7DmmaaLVtNGkF_72tXdTTHOZ5Z3gfhA4JnBMg_CKCpCwRGUtPKZwxkuaQwBaak4zLJIeUbKP5LzJDezG-AgCXVO6iGQFKZJrKObpcR4u9w13f-D7gRoc3GyKuWtz4tup8qNpn3L1YbIb1hPpPHSrdYqNbY8M-2nG6jvZgMxdofXP9tLxLVg-398urVWKo5JAwRwtRlKAZJ44yaowgXLgyJzYvoGQ0t6SwRFoJeWltRgvtjBQ8z1JdSEHZAp1Md9-D_-ht7FRTRWPrWrfW91FxKYgAAgOYTaAJPsZgnXoP1dDrSxFQozr1OHpRoxdFQf2oU2PuaPOgLxpb_ktNrgbgeAPoaHTtwtC_in-cGNwKwb4BOdJ2Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69717010</pqid></control><display><type>article</type><title>Use of tumour markers in monitoring the course of ovarian cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>RUSTIN, G. J. S ; NELSTROP, A. E ; BENTZEN, S. M ; PICCART, M. J ; BERTELSEN, K</creator><creatorcontrib>RUSTIN, G. J. S ; NELSTROP, A. E ; BENTZEN, S. M ; PICCART, M. J ; BERTELSEN, K</creatorcontrib><description>There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials.
The situations where measurement of CA 125 could alter the management of individual patients during therapy and at relapse were critically analysed. Precise definitions for response according to CA 125 were first developed and tested on 989 patients receiving first line therapy and have since been tested on over 2000 patients in phase 2 trials. Precise definitions for progression were developed from 71 patients during and on 255 patients both during and after initial chemotherapy.
In individual patient management, progression on initial chemotherapy can be demonstrated by serial rise in CA 125 suggesting the need for a change in therapy. A confirmed doubling of CA 125 from the upper limit of normal during follow up accurately predicts relapse. This endpoint needs prospective testing for use in clinical trials. Precise definitions of response based on a 50% or 75% fall in CA 125 levels accurately predicts whether a cytotoxic agent is active against ovarian cancer.
Precise definitions of response based on CA 125 should be used in phase 2 trials of new cytotoxic drugs.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/s0923-7534(20)31480-0</identifier><identifier>PMID: 10219449</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; CA-125 Antigen - analysis ; Chemotherapy ; Decision Making ; Disease Progression ; Female ; Host-tumor relations. Immunology. Biological markers ; Humans ; Medical sciences ; Neoplasm Recurrence, Local ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - pathology ; Pharmacology. Drug treatments ; Tumors</subject><ispartof>Annals of oncology, 1999, Vol.10, p.21-27</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2960-3f2b7bd0a361f232cc7167fd81e8b0d328e1be19e908dee52bafc976854ab9723</citedby><cites>FETCH-LOGICAL-c2960-3f2b7bd0a361f232cc7167fd81e8b0d328e1be19e908dee52bafc976854ab9723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,4024,4050,4051,23930,23931,25140,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1792977$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10219449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUSTIN, G. J. S</creatorcontrib><creatorcontrib>NELSTROP, A. E</creatorcontrib><creatorcontrib>BENTZEN, S. M</creatorcontrib><creatorcontrib>PICCART, M. J</creatorcontrib><creatorcontrib>BERTELSEN, K</creatorcontrib><title>Use of tumour markers in monitoring the course of ovarian cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials.
The situations where measurement of CA 125 could alter the management of individual patients during therapy and at relapse were critically analysed. Precise definitions for response according to CA 125 were first developed and tested on 989 patients receiving first line therapy and have since been tested on over 2000 patients in phase 2 trials. Precise definitions for progression were developed from 71 patients during and on 255 patients both during and after initial chemotherapy.
In individual patient management, progression on initial chemotherapy can be demonstrated by serial rise in CA 125 suggesting the need for a change in therapy. A confirmed doubling of CA 125 from the upper limit of normal during follow up accurately predicts relapse. This endpoint needs prospective testing for use in clinical trials. Precise definitions of response based on a 50% or 75% fall in CA 125 levels accurately predicts whether a cytotoxic agent is active against ovarian cancer.
Precise definitions of response based on CA 125 should be used in phase 2 trials of new cytotoxic drugs.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CA-125 Antigen - analysis</subject><subject>Chemotherapy</subject><subject>Decision Making</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Host-tumor relations. Immunology. Biological markers</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neoplasm Recurrence, Local</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1LxDAQhoMo7rr6E5QcRPRQnSRt0tyUxS9Y8KB7DmmaaLVtNGkF_72tXdTTHOZ5Z3gfhA4JnBMg_CKCpCwRGUtPKZwxkuaQwBaak4zLJIeUbKP5LzJDezG-AgCXVO6iGQFKZJrKObpcR4u9w13f-D7gRoc3GyKuWtz4tup8qNpn3L1YbIb1hPpPHSrdYqNbY8M-2nG6jvZgMxdofXP9tLxLVg-398urVWKo5JAwRwtRlKAZJ44yaowgXLgyJzYvoGQ0t6SwRFoJeWltRgvtjBQ8z1JdSEHZAp1Md9-D_-ht7FRTRWPrWrfW91FxKYgAAgOYTaAJPsZgnXoP1dDrSxFQozr1OHpRoxdFQf2oU2PuaPOgLxpb_ktNrgbgeAPoaHTtwtC_in-cGNwKwb4BOdJ2Dw</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>RUSTIN, G. J. S</creator><creator>NELSTROP, A. E</creator><creator>BENTZEN, S. M</creator><creator>PICCART, M. J</creator><creator>BERTELSEN, K</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>Use of tumour markers in monitoring the course of ovarian cancer</title><author>RUSTIN, G. J. S ; NELSTROP, A. E ; BENTZEN, S. M ; PICCART, M. J ; BERTELSEN, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2960-3f2b7bd0a361f232cc7167fd81e8b0d328e1be19e908dee52bafc976854ab9723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CA-125 Antigen - analysis</topic><topic>Chemotherapy</topic><topic>Decision Making</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Host-tumor relations. Immunology. Biological markers</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neoplasm Recurrence, Local</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUSTIN, G. J. S</creatorcontrib><creatorcontrib>NELSTROP, A. E</creatorcontrib><creatorcontrib>BENTZEN, S. M</creatorcontrib><creatorcontrib>PICCART, M. J</creatorcontrib><creatorcontrib>BERTELSEN, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUSTIN, G. J. S</au><au>NELSTROP, A. E</au><au>BENTZEN, S. M</au><au>PICCART, M. J</au><au>BERTELSEN, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of tumour markers in monitoring the course of ovarian cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>1999</date><risdate>1999</risdate><volume>10</volume><spage>21</spage><epage>27</epage><pages>21-27</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials.
The situations where measurement of CA 125 could alter the management of individual patients during therapy and at relapse were critically analysed. Precise definitions for response according to CA 125 were first developed and tested on 989 patients receiving first line therapy and have since been tested on over 2000 patients in phase 2 trials. Precise definitions for progression were developed from 71 patients during and on 255 patients both during and after initial chemotherapy.
In individual patient management, progression on initial chemotherapy can be demonstrated by serial rise in CA 125 suggesting the need for a change in therapy. A confirmed doubling of CA 125 from the upper limit of normal during follow up accurately predicts relapse. This endpoint needs prospective testing for use in clinical trials. Precise definitions of response based on a 50% or 75% fall in CA 125 levels accurately predicts whether a cytotoxic agent is active against ovarian cancer.
Precise definitions of response based on CA 125 should be used in phase 2 trials of new cytotoxic drugs.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10219449</pmid><doi>10.1016/s0923-7534(20)31480-0</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 1999, Vol.10, p.21-27 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69717010 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences CA-125 Antigen - analysis Chemotherapy Decision Making Disease Progression Female Host-tumor relations. Immunology. Biological markers Humans Medical sciences Neoplasm Recurrence, Local Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Pharmacology. Drug treatments Tumors |
| title | Use of tumour markers in monitoring the course of ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A59%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20tumour%20markers%20in%20monitoring%20the%20course%20of%20ovarian%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=RUSTIN,%20G.%20J.%20S&rft.date=1999&rft.volume=10&rft.spage=21&rft.epage=27&rft.pages=21-27&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/s0923-7534(20)31480-0&rft_dat=%3Cproquest_cross%3E69717010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69717010&rft_id=info:pmid/10219449&rfr_iscdi=true |